Case: 1:17-md-02804-DAP Doc #: 3862-25 Filed: 08/17/21 1 of 4. PageID #: 532286

## SJ-EXHIBIT 22

```
1
             IN THE UNITED STATES DISTRICT COURT
             FOR THE NORTHERN DISTRICT OF OHIO
 2.
                      EASTERN DIVISION
 3
    IN RE: NATIONAL
                        : MDL No. 2804
    PRESCRIPTION OPIATE
                            : Case No. 17-md-2804
 4
    LITIGATION
 5
    APPLIES TO ALL CASES : Hon. Dan A. Polster
 6
 7
                    HIGHLY CONFIDENTIAL
 8
 9
         SUBJECT TO FURTHER CONFIDENTIALITY REVIEW
10
11
12
                       JANUARY 4, 2019
13
14
         VIDEOTAPED DEPOSITION OF ANTHONY MOLLICA,
15
    taken pursuant to notice, was held at Marcus &
16
    Shapira, One Oxford Center, 35th Floor, Pittsburgh,
    Pennsylvania 15219, by and before Ann Medis,
17
18
    Registered Professional Reporter and Notary Public in
19
    and for the Commonwealth of Pennsylvania, on Friday,
20
    January 4, 2019, commencing at 8:06 a.m.
21
22
                 GOLKOW LITIGATION SERVICES
           877.370.3377 phone | 917.591.5672 fax
23
                       deps@golkow.com
24
25
```

- 1 requirements being held based on legal
- 2 requirements, et cetera.
- Q. Let's just, if we could, make a list of
- 4 these policies. So the first that I heard was
- 5 good decisions on dispensing.
- A. We supported pharmacists' right to make
- 7 professional judgments as to what was proper and
- 8 improper in terms of dispensing, made sure the
- 9 pharmacists knew that they had the right, final
- 10 right of decision making when it came to
- 11 dispensing.
- We had our controlled substance procedures
- that we made sure was distributed. We had audit
- 14 procedures that were done quarterly and documented
- in accordance with what our procedures and
- 16 policies were at the time. We had practices in
- 17 terms of document retention and what needed to be
- done in terms of proper ordering, training,
- 19 training on -- we had manuals and references
- 20 regarding not only the DEA, but Pharmacy Act and
- 21 fraud, waste and abuse policies, CBTs, annual
- meetings with a lot of discussions of what the
- obligation of pharmacists were and helped in any
- 24 way.
- We've had DEA inspections which were never --

- 1 never got any feedback that we weren't doing
- 2 anything other than what was required from us from
- 3 a legal perspective.
- 4 Q. So I just want to make sure I've got an
- 5 exhaustive list. One was good decisions on
- 6 dispensing. Then you said you gave pharmacists or
- 7 professionals the ability to make professional
- 9 judgments on dispensing controlled substances?
- 9 A. Yeah, supported by the Pharmacy Act,
- 10 yes.
- 11 O. And then the second one was controlled
- 12 substance procedures?
- 13 A. Again, Giant Eagle had a controlled
- 14 substance policy that's part of the control box,
- and the company made sure that we communicated
- 16 what those procedures are to the pharmacy.
- 17 Q. And what were those policies?
- 18 A. I can't recite them. It was part of the
- 19 control box.
- Q. When you say control box, what do you
- 21 mean by that?
- 22 A. There was a physical box in every
- 23 pharmacy that was a single place to look for
- 24 procedures, documents, records, that type of
- 25 thing. We called it the control box.